. Author manuscript; available in PMC: 2022 Mar 1.

Published in final edited form as: J Thorac Oncol. 2020 Dec 8;16(3):419–427. doi: 10.1016/j.jtho.2020.11.021

Table 1.

List of 52 genes whose mutations influence immunotherapy outcomes.

Gene name (% with mutations in MSK-TMB NSCLC cohort)
ABL1(2.0%), ASXL1(3.4%), ATM(6.6%), BCOR(4.0%), BRCA2(4.3%), BRIP1(3.7%), CARD11(4.0%), CD79B(1.4%), CDC73(0.9%), CIC(3.7%), EPHA3(10.6%), EPHA5(8.3%), EPHA7(5.1%),	EPHB1(3.7%), ERBB4(6.0%), ERCC4(2.0%), FGFR4(2.6%), FLT3(2.6%), FOXL2(1.4%), HGF(6.3%), INHBA(2.9%), JAK3(3.1%), MAX(2.0%), MDC1(4.0%), MED12(3.4%), MET(4.0%),	MGA(5.7%), MRE11(2.0%), MSH2(2.0%), NF2(3.4%), NFKBIA(0.9%), NOTCH1(4.0%), NOTCH2(3.1%), NTRK3(5.7%), NUF2(0.9%), PARP1(1.1%), PAX5(1.1%), PGR(4.3%), PIK3C2G(4.0%),	PIK3C3(3.7%), PIK3CG(7.7%), PIM1(0.9%), POLE(4.6%), PPM1D(1.4%), PPP2R1A(2.0%), PTPRD(12.3%), RET(2.9%), STAT3(0.9%), TENT5C(0.9%), TET1(2.3%), TSC2(2.6%), ZFHX3(7.7%)